EndoGastric Solutions will present new data on the company's Transoral Incisionless Fundoplication procedure for the treatment of gastroesophageal reflux disease at the Digestive Disease Week 2016 Annual Meeting, from May 21 to 24, in San Diego.
Here are four highlights:
1. The new data on the TIF procedure with the EsophyX device will include a meta-analysis poster presentation titled "Efficacy of Transoral Incisionless Fundoplication for Gastroesophageal Reflux Disease."
2. The meta-analysis reviewed ten randomized, controlled and prospective cohort clinical trials to evaluate the overall efficacy of the TIF procedure for treating patients with GERD.
3. The original EsophyX device was cleared by the FDA in 2007. The company launched the third generation EsophyX device, the EsophyX Z, in 2015.
4. Based in Redmond, Wash., EndoGastric Solutions is a medical device company focused on developing and commercializing incisionless surgical technology for the treatment of GERD.